Trials / Unknown
UnknownNCT01451905
GLP-1 Receptors in Normal Skin and Skin From Patients With Psoriasis
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- University Hospital, Gentofte, Copenhagen · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To examine GLP-1 receptors in skin of psoriasis patients compared with the skin of humans with no skin disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Liraglutide | Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylene glycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours. |
| DRUG | Placebo | The placebo pens contain saline and are administered in the same way and volume as Victoza. The placebo pens are specially prepared for this study and will be used in the study only |
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
- First posted
- 2011-10-14
- Last updated
- 2012-06-21
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT01451905. Inclusion in this directory is not an endorsement.